



Tripos Completes Sale of Discovery Informatics Business to Vector Capital Corporation

ST. LOUIS, Mar 20, 2007 (BUSINESS WIRE) -- Tripos, Inc. (Nasdaq:TRPS), announced today that it completed the sale of the assets of its Discovery Informatics business to affiliates of Vector Capital. Vector Capital is a San Francisco-based private equity boutique specializing in buyouts, spinouts and recapitalizations of established technology businesses.

Tripos received a final purchase price of \$26.2 million for the Discovery Informatics business. This represented an increased purchase price of approximately \$575,000 due to improved working capital of the business since the signing of the asset purchase agreement in November 2006.

Tripos used a portion of the proceeds to retire existing debt with LaSalle Bank and Horizon Technology Finance. Liquidation of the company will occur following resolution of all remaining corporate debts and obligations, and will commence approximately six months from now. Efforts to sell Tripos' Discovery Research business are continuing, although no assurance can be given that a transaction for this division can be completed on satisfactory terms.

General

This press release contains forward-looking statements concerning, among other things, Tripos' future prospects, which are affected by: (1) Tripos' ability to sell its Discovery Research business and certain other assets; (2) Tripos' ability to satisfy its creditors out of the proceeds of the Discovery Informatics and Discovery Research transactions and other available resources; (3) Tripos' ability to offset corporate tax liabilities on the sale of assets through the utilization of net operating loss carry-forwards; and (4) Tripos' ability to distribute any remaining cash to its stockholders. These statements are based upon numerous assumptions that Tripos cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, without limitations, those factors set forth in the company's Form 10-K for the fiscal year ended Dec. 31, 2005, and from time to time in the company's periodic filings with the Securities and Exchange Commission. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, Tripos does not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.

About Tripos, Inc.

Tripos (Nasdaq: TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Within Tripos' Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos' Discovery Research (DR) business, Tripos' medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Further information on Tripos can be found at <http://www.tripos.com>.

Tripos and the Tripos logo are registered trademarks of Tripos, Inc., and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners.

SOURCE: Tripos, Inc.

Tripos, Inc.
Senior Vice President and Chief Financial Officer
John Yingling, 314-647-1099
or
(Media only)
Waggener Edstrom Worldwide
Bioscience and Healthcare Practice
Account Director
Lisa Osborne, 202-326-0793
lisao@waggeneredstrom.com